Allarity Therapeutics (ALLR) Competitors $1.06 -0.02 (-1.39%) Closing price 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.94%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR vs. INCR, ANL, MCRB, BYSI, VTVT, UNCY, IOBT, BMEA, CLSD, and CABAShould you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include InterCure (INCR), Adlai Nortye (ANL), Seres Therapeutics (MCRB), BeyondSpring (BYSI), vTv Therapeutics (VTVT), Unicycive Therapeutics (UNCY), IO Biotech (IOBT), Biomea Fusion (BMEA), Clearside Biomedical (CLSD), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry. Allarity Therapeutics vs. InterCure Adlai Nortye Seres Therapeutics BeyondSpring vTv Therapeutics Unicycive Therapeutics IO Biotech Biomea Fusion Clearside Biomedical Cabaletta Bio InterCure (NASDAQ:INCR) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability, media sentiment and community ranking. Do institutionals and insiders have more ownership in INCR or ALLR? 8.3% of InterCure shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 0.0% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, INCR or ALLR? Allarity Therapeutics has lower revenue, but higher earnings than InterCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterCure$238.85M0.29-$16.83MN/AN/AAllarity TherapeuticsN/AN/A-$11.90MN/AN/A Is INCR or ALLR more profitable? InterCure's return on equity of 0.00% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InterCureN/A N/A N/A Allarity Therapeutics N/A -369.67%-100.06% Does the MarketBeat Community believe in INCR or ALLR? InterCure received 2 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave InterCure an outperform vote while only 33.33% of users gave Allarity Therapeutics an outperform vote. CompanyUnderperformOutperformInterCureOutperform Votes3100.00% Underperform VotesNo VotesAllarity TherapeuticsOutperform Votes133.33% Underperform Votes266.67% Which has more risk and volatility, INCR or ALLR? InterCure has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Does the media refer more to INCR or ALLR? In the previous week, InterCure's average media sentiment score of 0.75 beat Allarity Therapeutics' score of 0.00 indicating that InterCure is being referred to more favorably in the media. Company Overall Sentiment InterCure Positive Allarity Therapeutics Neutral SummaryInterCure beats Allarity Therapeutics on 8 of the 10 factors compared between the two stocks. Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLR vs. The Competition Export to ExcelMetricAllarity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.06M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E RatioN/A9.0626.7119.71Price / SalesN/A251.48386.12120.59Price / CashN/A65.8538.2534.62Price / Book0.006.456.774.50Net Income-$11.90M$143.98M$3.23B$248.22M7 Day Performance5.45%2.41%1.80%0.56%1 Month Performance7.48%4.56%11.10%13.17%1 Year Performance-94.45%-2.67%17.11%7.30% Allarity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLRAllarity Therapeutics0.1331 of 5 stars$1.07-1.4%N/A-93.8%$16.06MN/A0.0010Analyst UpgradeINCRInterCure0.7488 of 5 stars$1.52-4.4%N/A-52.9%$69.27M$238.85M0.00350ANLAdlai Nortye1.4765 of 5 stars$1.88+1.4%$9.00+380.0%-85.4%$69.19M$5M0.00127Gap DownHigh Trading VolumeMCRBSeres Therapeutics3.4649 of 5 stars$7.88+11.8%$73.67+834.9%-57.7%$68.81M$126.33M-34.26330BYSIBeyondSpringN/A$1.70+1.3%N/A-33.4%$68.58M$1.88M0.0080Gap DownVTVTvTv Therapeutics1.8354 of 5 stars$21.46+3.2%$35.50+65.4%-33.3%$68.46M$1.02M-4.749Earnings ReportUNCYUnicycive Therapeutics3.2325 of 5 stars$0.57+2.8%$5.50+872.6%-44.7%$68.22M$680,000.00-0.589News CoveragePositive NewsAnalyst RevisionIOBTIO Biotech3.0602 of 5 stars$1.03+3.0%$9.33+806.1%-17.8%$67.86MN/A-0.7530Analyst RevisionBMEABiomea Fusion2.6864 of 5 stars$1.77+8.6%$22.60+1,176.8%-87.5%$66.50MN/A-0.4450CLSDClearside Biomedical2.5076 of 5 stars$0.89+3.7%$5.25+489.6%-43.3%$66.37M$1.66M-1.9830CABACabaletta Bio2.2561 of 5 stars$1.29+8.4%$21.00+1,527.9%-85.3%$65.46MN/A-0.6050News CoverageEarnings ReportAnalyst RevisionGap Down Related Companies and Tools Related Companies InterCure Alternatives Adlai Nortye Alternatives Seres Therapeutics Alternatives BeyondSpring Alternatives vTv Therapeutics Alternatives Unicycive Therapeutics Alternatives IO Biotech Alternatives Biomea Fusion Alternatives Clearside Biomedical Alternatives Cabaletta Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
